STAN S31 FETAL HEART MONITOR

FDA Premarket Approval P020001

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the stan s31 fetal heart monitor. The device is indicated as an adjunct to fetal heart rate monitoring to determine whether obstetrical intervention is warranted when there is increased risk of developing metabolic acidosis. The device is intended for use in patients with: 1) planned vaginal delivery; 2) >36 completed weeks gestation; 3) singleton fetus; 4) vertex presentation; and 5) ruptured amniotic membranes.

DeviceSTAN S31 FETAL HEART MONITOR
Generic NameAnalyzer, Data, Obstetric
ApplicantNEOVENTA MEDICAL AB
Date Received2002-01-02
Decision Date2005-11-01
Notice Date2006-01-09
PMAP020001
SupplementS
Product CodeHEO 
Docket Number06M-0009
Advisory CommitteeObstetrics/Gynecology
Expedited ReviewNo
Combination Product No
Applicant Address NEOVENTA MEDICAL AB norra Agatan 32 se-431 35 molndal 
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P020001Original Filing
S009 2011-09-21 Real-time Process
S008 2011-07-07 30-day Notice
S007 2009-07-23 Normal 180 Day Track
S006 2009-09-11 Real-time Process
S005 2008-02-04 Real-time Process
S004 2007-10-11 Normal 180 Day Track
S003
S002 2007-08-13 Real-time Process
S001 2007-06-04 30-day Notice

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.